Tear, cornea, and aqueous humor concentrations of ciprofloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses.

OBJECTIVE To determine ocular tissue drug concentrations after topical ocular administration of 0.3% ciprofloxacin and 0.5% moxifloxacin in ophthalmologically normal horses. ANIMALS 24 ophthalmologically normal adult horses. PROCEDURES 0.3% ciprofloxacin and 0.5% moxifloxacin solutions (0.1 mL) were applied to the ventral conjunctival fornix of 1 eye in each horse as follows: group 1 (n = 8) at 0, 2, 4, and 6 hours; group 2 (8) at 0, 2, 4, 6, and 10 hours; and group 3 (8) at 0, 2, 4, 6, 10, and 14 hours. Tears, cornea, and aqueous humor (AH) were collected at 8, 14, and 18 hours for groups 1, 2, and 3, respectively. Drug concentrations were determined via high-performance liquid chromatography. RESULTS Median (25th to 75th percentile) concentrations of ciprofloxacin for groups 1, 2, and 3 in tears (μg/mL) were 53.7 (25.5 to 88.8), 48.5 (19.7 to 74.7), and 24.4 (15.4 to 67.1), respectively; in corneal tissue (μg/g) were 0.95 (0.60 to 1.02), 0.37 (0.32 to 0.47), and 0.48 (0.34 to 0.95), respectively; and in AH were lower than the limit of quantification in all groups. Concentrations of moxifloxacin for groups 1, 2, and 3 in tears (μg/mL) were 188.7 (44.5 to 669.2), 107.4 (41.7 to 296.5), and 178.1 (70.1 to 400.6), respectively; in corneal tissue (μg/g) were 1.84 (1.44 to 2.11), 0.78 (0.55 to 0.98), and 0.77 (0.65 to 0.97), respectively; and in AH (μg/mL) were 0.06 (0.04 to 0.08), 0.03 (0.02 to 0.05), and 0.02 (0.01 to 0.04), respectively. Corneal moxifloxacin concentrations were significantly higher in group 1 than groups 2 and 3. CONCLUSIONS AND CLINICAL RELEVANCE After topical ocular administration, fluoroquinolones can reach therapeutic concentrations in tears and corneal tissue of horses, even when there is an intact epithelium.

[1]  F. Hu,et al.  Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells , 2010, Eye.

[2]  N. Nayak,et al.  In Vitro Susceptibility of Bacterial Keratitis Isolates to Fourth-Generation Fluoroquinolones , 2010, European journal of ophthalmology.

[3]  P. Asbell,et al.  Evaluation of Toxicity of Commercial Ophthalmic Fluoroquinolone Antibiotics as Assessed on Immortalized Corneal and Conjunctival Epithelial Cells , 2008, Cornea.

[4]  M. Raizman,et al.  Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. , 2008, American journal of ophthalmology.

[5]  S. Cox,et al.  Pharmacokinetics of topically applied ciprofloxacin in equine tears. , 2005, Veterinary ophthalmology.

[6]  A. Duggirala,et al.  Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. , 2007, Indian journal of ophthalmology.

[7]  D. Hendrix,et al.  Bacterial isolates and antimicrobial susceptibilities in equine bacterial ulcerative keratitis (1993--2004). , 2010, Equine veterinary journal.

[8]  E. Romanowski,et al.  An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. , 2005, Ophthalmology.

[9]  D. Dahlin,et al.  Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. , 2005, Survey of ophthalmology.

[10]  H. Erb,et al.  Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. , 2003, Veterinary ophthalmology.

[11]  M. Nordlund,et al.  Concentrations of Levofloxacin, Ofloxacin, and Ciprofloxacin in Human Corneal Stromal Tissue and Aqueous Humor After Topical Administration , 2004, Cornea.

[12]  C. Kim,et al.  Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro , 2004, Clinical & experimental ophthalmology.

[13]  P. Sauer,et al.  Changes in antibiotic resistance in equine bacterial ulcerative keratitis (1991-2000): 65 horses. , 2003, Veterinary ophthalmology.

[14]  M. Callegan,et al.  Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens , 2003, Advances in therapy.

[15]  E. Romanowski,et al.  Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. , 2003, American journal of ophthalmology.

[16]  S. Duman,et al.  Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous , 2003, Journal of cataract and refractive surgery.

[17]  M. Raizman,et al.  Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. , 2002, Clinical therapeutics.

[18]  D. Ince,et al.  Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin inStaphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.

[19]  H. Flynn,et al.  Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. , 1999, American journal of ophthalmology.

[20]  J. Baum,et al.  Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review , 1999 .

[21]  U. Yasar,et al.  Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration. , 1999, Ophthalmic surgery and lasers.

[22]  A. Akkan,et al.  Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. , 1997, International journal of clinical pharmacology and therapeutics.

[23]  D. Acosta,et al.  Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[24]  Y. Shimomura,et al.  Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. , 1996, Japanese journal of ophthalmology.

[25]  J. Diamond,et al.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. , 1995, The British journal of ophthalmology.

[26]  C. Buggé,et al.  Tear Concentrations of Topically Applied Ciprofloxacin , 1994, Cornea.

[27]  J. Cowden,et al.  Corneal stromal penetration of topical ciprofloxacin in humans. , 1993, Ophthalmology.

[28]  D. Tang-Liu,et al.  Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms , 1990, Antimicrobial Agents and Chemotherapy.

[29]  J. Prescott,et al.  In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. , 1990, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[30]  W. Fales,et al.  Bacterial and fungal isolates from Equidae with ulcerative keratitis. , 1983, Journal of the American Veterinary Medical Association.